Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
First reported by TechCrunch ·
The cost of developing a new drug candidate falls by roughly $2 billion, saving your company millions.
Isomorphic Labs, an AI drug discovery company spun out of Google's DeepMind, has secured $5 billion in a Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and all existing backers, including Alphabet's GV and Capital G. The company utilizes an AI engine, built upon DeepMind's AlphaFold protein-folding model, to design drugs and has reported positive preclinical results in oncology and immunology. Isomorphic Labs has established partnerships with major pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson. This substantial funding follows a $2.1 billion Series B round in May and will support the continued development of its drug-design engine and expansion into new therapeutic areas. The fundraising occurred after CEO Demis Hassabis transitioned from leading DeepMind to fully focus on Isomorphic Labs.
This record-breaking funding round for an AI drug discovery startup signals a significant acceleration in venture capital interest and investment in the sector. The substantial capital infusion suggests a strong market validation for AI-driven therapeutic development, moving beyond early-stage research to tangible progress towards clinical trials. It highlights a growing trend where AI platforms are not just tools for discovery but are aiming to become integrated drug developers themselves, potentially disrupting traditional pharmaceutical R&D timelines and costs. The involvement of major venture capital firms and existing strategic investors underscores a belief in the transformative potential of AI to unlock new treatments and address unmet medical needs, positioning Isomorphic Labs as a key player in this evolving landscape.
The success of Isomorphic Labs' fundraising could incentivize other AI biotech startups to pursue similar ambitious funding goals, potentially leading to increased competition and a rapid scaling of AI capabilities in drug development. Pharmaceutical giants' continued engagement with these AI platforms, through partnerships and investments, indicates a strategic shift towards incorporating AI into their own pipelines, not just as an external resource but as a fundamental component of future drug discovery. This trend may also lead to greater collaboration between AI specialists and traditional life sciences companies, blurring the lines between tech and biotech and fostering an environment of rapid innovation and knowledge exchange. The market should watch for how these AI-driven candidates progress through clinical trials, as this will be the ultimate test of their efficacy and the value proposition of AI in bringing new medicines to patients.
AI-written summary. May contain errors.